Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation

• Mohammad Raeiszadeh,
• Annette Pachnio,
• Jusnara Begum,
• Charles Craddock,
• Paul Moss,
• Frederick E. Chen

Affiliations

Mohammad Raeiszadeh

NHS Blood and Transplant, Birmingham, UK;School of Cancer Sciences, University of Birmingham, Birmingham, UK

Annette Pachnio

School of Cancer Sciences, University of Birmingham, Birmingham, UK

Jusnara Begum

School of Cancer Sciences, University of Birmingham, Birmingham, UK

Charles Craddock

School of Cancer Sciences, University of Birmingham, Birmingham, UK;Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Paul Moss

School of Cancer Sciences, University of Birmingham, Birmingham, UK;Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Frederick E. Chen

NHS Blood and Transplant, Birmingham, UK;School of Cancer Sciences, University of Birmingham, Birmingham, UK;Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK